




CORRECTION

Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

Macy M. Goldbach, BS¹ , Laura Burkbauer, BA¹, Tina Bharani, MD¹, Austin D. Williams, MD, MEd³, Luke Keele, PhD², Jami Rothman, MD^{1,4}, Rachel Jankowitz, MD⁴, and Julia C. Tchou, MD, PhD, FACS^{1,4}

¹Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²Division of Epidemiology and Biostatistics, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Lankenau Medical Center, Wynnewood, PA; ⁴Rena Rowan Breast Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

CORRECTION TO: ANN SURG ONCOL
[HTTPS://DOI.ORG/10.1245/S10434-021-10287-5](https://doi.org/10.1245/S10434-021-10287-5)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The electronic supplementary material for this article has been updated.

The original article can be found online at <https://doi.org/10.1245/s10434-021-10287-5>.

© Society of Surgical Oncology 2021

Published Online: 15 July 2021

M. M. Goldbach, BS
e-mail: Julia.Tchou@penncmedicine.upenn.edu

J. C. Tchou, MD, PhD, FACS
e-mail: Julia.Tchou@penncmedicine.upenn.edu